Harmony Biosciences is trading at $38.11, down 5.38%, following the announcement that Peter Anastasiou will succeed Jeffrey Dayno as President and CEO, effective January 1, 2027. - Dayno will retire at the end of 2026 but serve as a non-executive advisor through 2027. - The company also reiterated its full-year 2026 WAKIX net revenue guidance.